ArticleOncotarget2016
Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 107 citations in OpenAlex.
- Sialylation in Colorectal Cancer Rewires Antitumor Immunity at the Peritoneal Metastatic Site.European journal of immunology · 2026Article
- Neu5Ac promotes high-fat diet-induced progression of atherosclerosis in ApoE-deficient mice.Experimental animals · 2026Article
- Sialic acids modulate immune responses in cancer: Therapeutic opportunities.The Journal of biological chemistry · 2026Review
- Analysis of the Functional Impact of Glycosylation on Immune Checkpoint Proteins.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Tumor desialylation surpasses anti-PD-L1 checkpoint therapy in restoring anti-tumor immunity in a murine model for colorectal cancer.International journal of cancer · 2025Article
- Targeting Sialidase to PD1 Enhances T cell Function and Tumor Control.ACS central science · 2025Article
- Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance.Science advances · 2025Article
- Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells.Molecular oncology · 2025Review
- Analysis of cancer-associated glycosyltransferases reveals novel targets of non-small cell lung cancer pathogenesis.Frontiers in oncology · 2025Article
- Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.International journal of biological sciences · 2025Review
- Solute Carrier Family 35 A2 (SLC35A2) Promotes Tumor Progression through MYC-Mediated Pathways in Colorectal Cancer.International journal of medical sciences · 2025Article
- Article
- Collagen Mineralization Decreases NK Cell-Mediated Cytotoxicity of Breast Cancer Cells via Increased Glycocalyx Thickness.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- T-antigen as a biomarker of progression-free survival in patients with glioblastoma.Annals of clinical and translational neurology · 2024Article
- Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer.Glycobiology · 2024Article
- Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.Communications biology · 2024Article
- COLLAGEN MINERALIZATION DECREASES NK CELL-MEDIATED CYTOTOXICITY OF BREAST CANCER CELLS VIA INCREASED GLYCOCALYX THICKNESS.bioRxiv : the preprint server for biology · 2024Article
- Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.International journal of biological sciences · 2024Review
- Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.Journal for immunotherapy of cancer · 2023Article
- The new progress in cancer immunotherapy.Clinical and experimental medicine · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased presence of sialylated glycans on the tumor surface has been linked to poor prognosis, yet the effects on tumor-specific T cell immunity are hardly studied. We here show that hypersialylation of B16 melanoma substantially influences tumor growth by preventing the formation of effector T cells and facilitating the presence of high regulatory T cell (Treg) frequencies. Knock-down of the sialic acid transporter created "sialic acid low" tumors, that grew slower in-vivo than hypersialylated tumors, altered the Treg/Teffector balance, favoring immunological tumor control. The enhanced effector T cell response in developing "sialic acid low" tumors was preceded by and dependent on an increased influx and activity of Natural Killer (NK) cells. Thus, tumor hypersialylation orchestrates immune escape at the level of NK and Teff/Treg balance within the tumor microenvironment, herewith dampening tumor-specific T cell control. Reducing sialylation provides a therapeutic option to render tumors permissive to immune attack.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.